Increased disease control with Roche's Ocrevus in MS, analyses show

Swiss pharma major Roche (ROG: SIX) has shared the results of new analyses of three Ocrevus (ocrelizumab) Phase III studies in relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

Ocrevus increased disease control in patients with RMS and PPMS in separate post-hoc analyses which are being presented at this week’s European Committee for Treatment and Research in Multiple Sclerosis.

In these analyses, two composite endpoints measured disease control using a combination of clinical and MRI outcomes, namely no evidence of disease activity (NEDA) in patients with RMS and no evidence of progression (NEP) in patients with PPMS. These composite endpoints are emerging as new treatment targets.